Redeye provides an initial take following the release of Optomed’s Q1 2025 report. Sales came in better than expected (+13%), and we highlight that the US business (Aurora AEYE) is starting to have a visible impact on total sales. Furthermore, we argue that this is a solid report by Optomed, and we will provide a research update shortly, expecting to make only minor estimate changes.
LÄS MER
